CD34 and acute myeloid leukemia: However, our data revealed that a strategy based solely on the expression of these markers cannot be used to clearly isolate the AML blasts with recurrent genetic abnormalities or normal myHPCs, due to the inability to avoid the contamination of the CD45low CD117+ CD34± HLA-DRvariable (low to high) population with undesirable mature cells.